Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579616 | 1.00 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL2482179 | 0.85 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL6639407 | 0.84 | GCGR (0.30) | KCNH2 | |
| SCHEMBL1498592 | 0.83 | RAB9A (0.32) | KCNH2 | |
| SCHEMBL30070612 | 0.79 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL12615482 | 0.79 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL3748371 | 0.79 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL246415 | 0.77 | CCR1 (0.39) | KCNH2 | |
| SCHEMBL29865866 | 0.77 | CCR1 (0.39) | KCNH2 | |
| SCHEMBL12616013 | 0.76 | SYK (0.32) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952374-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-116724038-A | Bicyclic compounds | 安力高医药股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4232450-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022087011-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119385-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-2276759-B1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | LILLY CO ELI (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7932274-B2 | 3-indazolyl-4-pyridylisothiazoles | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2276759-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | Eli Lilly & Company (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119385-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KCNH2 1842/4885 |
| US-11952374-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | KCNH2 1842/4885 |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | CYP3A4, IPO4, JAK3 | KCNH2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.